Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM1BP4_ModerateBP6
The NM_007294.4(BRCA1):āc.4934G>Cā(p.Arg1645Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000211 in 1,614,214 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Likely_benign. Variant got -1 ACMG points.
PM1
In a domain BRCT 1 (size 94) in uniprot entity BRCA1_HUMAN there are 74 pathogenic changes around while only 17 benign (81%) in NM_007294.4
BP4
Computational evidence support a benign effect (MetaRNN=0.08958271).
BP6
Variant 17-43070980-C-G is Benign according to our data. Variant chr17-43070980-C-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 142312.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=6, Benign=1, not_provided=1, Uncertain_significance=2}.
Likely benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Mar 08, 2018
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Likely benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Apr 25, 2016
- -
Uncertain significance, criteria provided, single submitter
curation
Sema4, Sema4
Aug 20, 2021
- -
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1Benign:1Other:1
not provided, no classification provided
in vitro
Brotman Baty Institute, University of Washington
-
- -
Benign, criteria provided, single submitter
clinical testing
Mendelics
Aug 22, 2023
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Counsyl
Apr 06, 2016
- -
not provided Benign:2
Likely benign, criteria provided, single submitter
clinical testing
GeneDx
Jan 12, 2021
Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 28781887, 30209399) -
Likely benign, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Jun 02, 2023
- -
not specified Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Jan 24, 2024
Variant summary: BRCA1 c.4934G>C (p.Arg1645Thr) results in a non-conservative amino acid change located in the BRCT domain (IPR001357) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251254 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.4934G>C in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome has been reported. A co-occurrence with a pathogenic variant has been reported by a ClinVar submitter (BRCA2 unspecified variant), providing supporting evidence for a benign role. Multiple publications report experimental evidence evaluating an impact on protein function (e.g. Woods_2016, Findlay_2018, Fernandes_2019, Bouwman_2020). These results showed no damaging effect of this variant on homology directed repair (HDR) activity. The following publications have been ascertained in the context of this evaluation (PMID: 32546644, 30765603, 30209399, 28781887, Thompson_2016). ClinVar contains an entry for this variant (Variation ID: 142312). Based on the evidence outlined above, the variant was classified as likely benign. -
Malignant tumor of breast Benign:1
Likely benign, no assertion criteria provided
clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System
-
The p.Arg1645Thr variant has not been reported in the literature but has been listed in the Exome Variant Server database. The p.Arg1645 residue is not conserved in mammals, and the variant amino acid Threonine (Thr) is present in the opossum and chicken at this position, increasing the likelihood that an alteration to this residue may not have functional significance. Computational analyses (PolyPhen, SIFT, AlignGVGD) do not predict any effect on the protein function, however, this information is not predictive enough to assume pathogenicity. The variant is listed in the dbSNP database (ID#:rs70953661) as coming from a "clinical source" but no frequency information was provided, and so the prevalence of this variant in the population is not known. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as predicted benign. -
BRCA1-related disorder Benign:1
Likely benign, no assertion criteria provided
clinical testing
PreventionGenetics, part of Exact Sciences
Mar 03, 2023
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Hereditary breast ovarian cancer syndrome Benign:1
Likely benign, criteria provided, single submitter